Skip to main content
Equibles
DWTX logo

DWTX · Dogwood Therapeutics, Inc.

Track DWTX — free

Use DWTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.63 +0.05 (+1.94%) At close · Sep 1
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Accordingly, there is substantial doubt about the Company's ability to operate as a going concern within one year after the issuance date of these condensed consolidated financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$90.42M
Shares
33.99M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.63 Open$2.70 Day$2.55–2.73 52W close$1.34–7.91 Avg vol 30d68K Short int50K · 0.1% float · 1.0d Short vol55% Last earningsMay 14, 2026 DataOct 2024–Sep 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Oct 9, 2024; bars on opposite sides are not compared.

Up next

Next earnings call
Dec 24, 2026 Est · unconfirmed · in 16 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.67
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −5%
below
Price vs 50-day avg +46%
above
RSI (14) 68
neutral
MACD trend Positive
52-week position 20%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +47%
trailing
6-month return −6%
trailing
YTD return −37%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+15% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.15% of float · ▼ -32.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
15 holders — mid 3-yr range
Squeeze score 41
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 99%
annualized · 1-yr
Max drawdown −83%
past year
ATR 7.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−5% Neutral
Price vs 50-day avg
+46% Bullish
RSI (14)
68 Neutral
MACD trend
Positive Bullish
52-week position
20% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+15% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.15% of float · ▼ -32.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
15 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $3 · 20% Range high $8
vs 200-day avg -5% vs 50-day avg +46%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DWTX
Dogwood Therapeutics, Inc.
this stock
$90.42M -36.8% — — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +20.8% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +6.7% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $64.16B +22.3% — — 1.9%
MRNA
Moderna, Inc.
 $61.59B +423.1% +4.3% — 13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
15
% held
11.3%
Net QoQ
+209.4K sh
Top holder
ARMISTICE CAPITAL, LLC
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Falling
Shares short
50.0K
Days to cover
1.0d
Change
-23.8K sh
View
Short Volume
Short vol %
55%
As of
Sep 1, 2026
Short Total
View
Fails to Deliver
FTD shares
1.0K
Value
$1.7K
As of
Aug 4, 2026
View
Off-Exchange
Off-exchange %
69.3%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-34.3M
EPS diluted
$-7.13
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
13
View
Earnings & Events
Earnings Calls
Last call
Aug 3, 2026
View

Performance

Raw-price comparisons begin at the captured split on Oct 9, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
DWTX -1.9% +46.9% -6.4% +1.9% -36.8%
SPY -0.5% -1.2% +12.6% -0.7% +11.7%
vs SPY -1.3% +48.2% -19.0% +2.6% -48.5%
Key facts CIK 1818844 CUSIP 92829J203 13F (30d) 15 filings 14 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)